Pharmacist Mental Health | Pharmacogenomics On-Demand 1h

The PRIME Care Trial shows benefits of using pharmacogenomics to treat mental health conditions. Take this course to learn how using this information can gain better outcomes in treating depression.

Learning Objectives

Upon successful completion of this application-based course, participants should be able to:
1. Describe how pharmacogenomics (PGx) testing can impact medications related to depression.
2. Recognize the impact of a multigene PGx panel on remission and response rates in patients with depression.
3. Describe how PGx testing impacts rates of drug-gene interactions.
4. Discuss the strengths, limitations, and results of the PRIME Care Trial.
5. Develop a conclusion for the role of pharmacogenomics in patient-centered depression care based on a clinical trial.

Article Information

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read the article cited below.

Oslin DW, Lynch KG, Shih M, et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022;328(2):151–161. doi:10.1001/jama.2022.9805

Faculty

Jordan Baye, PharmD, MA, BCPS

Assistant Professor
South Dakota State University College of Pharmacy & Allied Health Professions

Disclosures:

Dr. Baye has no relevant financial relationships with ineligible companies to disclose.

Course Details